Ayurvedic Treatment of Polycystic Ovarian Syndrome(PCOS)

An open - label randomized controlled clinical trial to assess the efficacy of Shatapushpa taila nasya and Shatapushpa taila uttarabasti along with oral administration of Shatapushpa choorna on ovulatory factor in women with Poly Cystic Ovarian Syndrome - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084595

Enrollment

Registered

2025-04-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Female(married)patients between the age of 20-40yrs, willing to participate and diagnosed as having PCOS as per Rotterdam criteria ESHRE/ASRM 2003, Anovulation {Confirmed by USG TVS Follicular study From Day 11 Till required time period, Females fit for Nasyakarma.

Exclusion criteria

Exclusion criteria: Ovarian tumors, Chronic systemic disorders like Thyroid dysfunction, HTN, DM, TB Endometriosis, Uterine Fibroids, Uterine Polyps and Carcinoma, Congenital malformations. Patients taking medications like metformin, combination birth control pills, Progestin therapy, Spironolactone, ovulation induction therapy like Clomiphene, Letrozole, Gonadotropins. Patients taking Antiepileptics, Antipsychotics and Oral contraceptive pills Any active pelvic infection, any debilitating diseases will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of Therapy on Ovulation ( assesed by USG(TVS) Follicular study starting from day 11th of menstrual cycle up to required time period in that menstrual cycle in women with Polycystic Ovarian Syndrome. Timepoint: 0th day(baseline), 90th day, 180th day	—

Secondary

Measure	Time frame
To evaluate the effect on ovarian reserve markers (Change in Serum AMH Levels, LH/FSH Ratio, Ovarian Volume (assessed by using USG TVS.)Timepoint: At baseline(0th day), 90th day, 180th day;Reduction in Interval between menstrual cycle ( No of days between two menstrual cycles)Timepoint: At Baseline(0th day), 90thday, 180th day;Reduction in Insulin resistance, Lipid profile(Total cholestrol, Triglycerides, HDL, LDL levels), Body Mass Index Timepoint: At Baseline(0th day), 90thday, 180th day	—

Measure

Time frame

To evaluate the effect on ovarian reserve markers (Change in Serum AMH Levels, LH/FSH Ratio, Ovarian Volume (assessed by using USG TVS.)Timepoint: At baseline(0th day), 90th day, 180th day;Reduction in Interval between menstrual cycle ( No of days between two menstrual cycles)Timepoint: At Baseline(0th day), 90thday, 180th day;Reduction in Insulin resistance, Lipid profile(Total cholestrol, Triglycerides, HDL, LDL levels), Body Mass Index Timepoint: At Baseline(0th day), 90thday, 180th day

—

Countries

India

Contacts

Public ContactDr Swati V Gaikwad

All India Institute Of Ayurveda

swativgaikwad369@gmail.com9270825656

Outcome results